Telomir Pharmaceuticals

TELO

Market cap $74.3M

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model. MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporting the biological activity of Telomir-Zn in Wilson's disease.

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC).

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newswire / April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ("TELI").

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic drivers of cancer, today announced new in vitro data demonstrating that Telomir-1 (Telomir-Zn) induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer (TNBC).

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental biological mechanisms implicated in cancer, aging, and degenerative disease, today announced new cellular study results demonstrating that Telomir-1, in the form of Telomir-Zn, induces a rapid and coordinated intracellular redistribution of zinc and iron.

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced results from a completed efficacy study evaluating Telomir-1 (Zn-Telomir) in zebrafish tumor xenograft animal models of triple-negative breast cancer (TNBC).

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir).

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today reported new preclinical findings demonstrating that its lead therapeutic candidate, Telomir-1, reduced PSA (prostate-specific antigen) levels in androgen-responsive human prostate cancer cells (LNCaP).